fashion -WSS

fashion

author：knowledge 2025-09-30 22:27:48 - browse：7

Illumina, the largest maker of DNA-sequencing technology and a storied name in the biotechnology industry, named Jacob Thaysen, a 10-year-veteran at life sciences-tools firm Agilent, as its new CEO.

The appointment follows a bitter board fight that ended with the departure of Francis deSouza, who had been Illumina’s CEO since 2016. The battle, tipped off by Illumina’s troubled acquisition of cancer diagnostics firm Grail, had involved a proxy fight staged by activist investor Carl Icahn.

During the battle, there had been speculation that Jay Flatley, deSouza’s predecessor, could return. Under Flatley, Illumina had grown from an upstart to the dominant player in a field that has proved pivotal for medical research and delivered sizable returns to investors.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Testing for cancer recurrence creates a new limbo for patients

WSS

Emergency medicine has repudiated 'excited delirium.' Now what?

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Readout Newsletter: What happened with Sarepta's Duchenne data

What to make of Biden’s latest efforts on cancer research

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Acelyrin, a rare IPO success, stumbles in its first big test

leisure time

fashion

explore

How one medical school became remarkably diverse

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

In Memoriam: Notable people who died in 2023

Cassava reveals details — and problems — with Alzheimer's study

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA approves updated Covid vaccines

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA approves updated Covid vaccines

Affirmative action in medical school literally saved lives

IRA could hurt research into orphan drugs for rare diseases

knowledge

New Covid vaccine is recommended for everyone 6 months or older

Will the IRA bring competition to the biologics market?

Cassava reveals details — and problems — with Alzheimer's study

Telehealth options flood the market as retailers push virtual care

First Opinion Podcast: How to protect health care in times of war

Cassava reveals details — and problems — with Alzheimer's study

focus

leisure time

explore

hotspot